-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: iNature (ID: Plant_ihuman) iNature in rodents, obesity and aging can impair the biosynthesis of nicotinamide adenine dinucleotide (NAD +), leading to metabolic dysfunction.
The availability of nicotinamide mononucleotide (NMN) is the rate-limiting factor in mammalian NAD+ biosynthesis.
On April 22, 2021, the team of Samuel Klein of the University of Washington in the United States published a research paper entitled "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women" in Science Online.
The study conducted a 10-week randomized, placebo-controlled, A double-blind trial to evaluate the effect of NMN supplementation on the metabolic function of women with overweight or obesity after menopause.
After NMN supplementation, insulin-stimulated glucose utilization was assessed using a hyperinsulinemic-hyperglycemic clamp, and skeletal muscle insulin signaling (phosphorylation of AKT and mTOR) increased, but did not change after placebo treatment.
NMN supplementation up-regulates the expression of platelet-derived growth factor receptor β and other genes related to muscle remodeling.
These results indicate that NMN can increase muscle insulin sensitivity, insulin signaling and remodeling in overweight or obese pre-diabetic women.
Nicotinamide adenine dinucleotide (NAD +) is a common substrate for enzymes that consume NAD +, and these enzymes are essential for regulating a variety of biological processes.
In rodents, insufficient biosynthesis of NAD+ in the liver, adipose tissue, and skeletal muscle is the pathogenesis of obesity and aging-related metabolic abnormalities (including insulin resistance, β-cell dysfunction, and liver steatosis).
The main pathway of NAD + biosynthesis involves the conversion of nicotinamide to nicotinamide mononucleotide (NMN) and the subsequent conversion of NMN to NAD +.
The production of NMN is a key rate-limiting factor in mammalian NAD+ biosynthesis.
Systemic NMN administration in obese mice fed a high-fat diet can increase tissue NAD+ concentration and improve glucose tolerance, insulin sensitivity and β-cell function, while long-term NMN fed regular food can reduce age-related insulin resistance.
The beneficial effects of NMN supplements in rodents have led to the rapid commercial development of NMN products in humans, and NMN is sold in the United States and other countries as a supplement to improve glucose control, enhance energy metabolism and reverse the metabolic complications of aging .
Although NMN is found in natural foods, including edamame, broccoli, avocado, tomatoes, and milk, the daily intake of NMN as part of a healthy diet may be less than 2 mg/day.
The dose of NMN in commercial products ranges from 50 mg to 150 mg/capsule, and some consumers take 2 150 mg capsules per day.
However, the effect on metabolism of people who supplement with NMN every day is not yet known.
The study conducted a 10-week randomized, placebo-controlled, double-blind trial to evaluate the effects of supplementation of NMN on the metabolic function of women with overweight or obesity after menopause.
After supplementation with NMN, insulin-stimulated glucose utilization was assessed using a hyperinsulinemic-hyperglycemic clamp.
Skeletal muscle insulin signaling (phosphorylation of AKT and mTOR) increased, but did not change after placebo treatment.
NMN supplementation up-regulates the expression of platelet-derived growth factor receptor β and other genes related to muscle remodeling.
These results indicate that NMN can increase muscle insulin sensitivity, insulin signaling and remodeling in overweight or obese pre-diabetic women.
Reference message: DOI: 10.
1126/science.
abe9985
The availability of nicotinamide mononucleotide (NMN) is the rate-limiting factor in mammalian NAD+ biosynthesis.
On April 22, 2021, the team of Samuel Klein of the University of Washington in the United States published a research paper entitled "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women" in Science Online.
The study conducted a 10-week randomized, placebo-controlled, A double-blind trial to evaluate the effect of NMN supplementation on the metabolic function of women with overweight or obesity after menopause.
After NMN supplementation, insulin-stimulated glucose utilization was assessed using a hyperinsulinemic-hyperglycemic clamp, and skeletal muscle insulin signaling (phosphorylation of AKT and mTOR) increased, but did not change after placebo treatment.
NMN supplementation up-regulates the expression of platelet-derived growth factor receptor β and other genes related to muscle remodeling.
These results indicate that NMN can increase muscle insulin sensitivity, insulin signaling and remodeling in overweight or obese pre-diabetic women.
Nicotinamide adenine dinucleotide (NAD +) is a common substrate for enzymes that consume NAD +, and these enzymes are essential for regulating a variety of biological processes.
In rodents, insufficient biosynthesis of NAD+ in the liver, adipose tissue, and skeletal muscle is the pathogenesis of obesity and aging-related metabolic abnormalities (including insulin resistance, β-cell dysfunction, and liver steatosis).
The main pathway of NAD + biosynthesis involves the conversion of nicotinamide to nicotinamide mononucleotide (NMN) and the subsequent conversion of NMN to NAD +.
The production of NMN is a key rate-limiting factor in mammalian NAD+ biosynthesis.
Systemic NMN administration in obese mice fed a high-fat diet can increase tissue NAD+ concentration and improve glucose tolerance, insulin sensitivity and β-cell function, while long-term NMN fed regular food can reduce age-related insulin resistance.
The beneficial effects of NMN supplements in rodents have led to the rapid commercial development of NMN products in humans, and NMN is sold in the United States and other countries as a supplement to improve glucose control, enhance energy metabolism and reverse the metabolic complications of aging .
Although NMN is found in natural foods, including edamame, broccoli, avocado, tomatoes, and milk, the daily intake of NMN as part of a healthy diet may be less than 2 mg/day.
The dose of NMN in commercial products ranges from 50 mg to 150 mg/capsule, and some consumers take 2 150 mg capsules per day.
However, the effect on metabolism of people who supplement with NMN every day is not yet known.
The study conducted a 10-week randomized, placebo-controlled, double-blind trial to evaluate the effects of supplementation of NMN on the metabolic function of women with overweight or obesity after menopause.
After supplementation with NMN, insulin-stimulated glucose utilization was assessed using a hyperinsulinemic-hyperglycemic clamp.
Skeletal muscle insulin signaling (phosphorylation of AKT and mTOR) increased, but did not change after placebo treatment.
NMN supplementation up-regulates the expression of platelet-derived growth factor receptor β and other genes related to muscle remodeling.
These results indicate that NMN can increase muscle insulin sensitivity, insulin signaling and remodeling in overweight or obese pre-diabetic women.
Reference message: DOI: 10.
1126/science.
abe9985